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Abstract
Background: A number of studies have suggested a link between the patient's psyche and the
course of inflammatory bowel disease (IBD). Although pharmacotherapy with antidepressants has
not been widely explored, some investigators have proposed that treating psychological co-
morbidities with antidepressants may help to control disease activity. To date a systematic analysis
of the available studies assessing the efficacy of antidepressants for the control of somatic
symptoms in IBD patients has not been performed.
Methods: We searched electronic databases, without any language restriction. All relevant papers
issued after 1990 were examined.
Results: 12 relevant publications were identified. All of them referred to non-randomised studies.
Antidepressants reported in these publications included paroxetine, bupropion, amitriptyline,
phenelzine, and mirtazapine. In 10 articles, paroxetine, bupropion, and phenelzine were suggested
to be effective for treating both psychological and somatic symptoms in patients suffering from IBD.
Amitriptyline was found ineffective for treating somatic symptoms of IBD. Mirtazapine was not
recommended for IBD patients.
Conclusion: Although most of reviewed papers suggest a beneficial effect of treatment with
antidepressants in patients with IBD, due to the lack of reliable data, it is impossible to judge the
efficacy of antidepressants in IBD. Properly designed trials are justified and needed based upon the
available uncontrolled data.
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Background
Inflammatory bowel disease (IBD) is a group of relapsing
incurable diseases of the gastrointestinal tract. There is
ongoing active research to find a curative treatment and
understand the aetiology of IBD in immunology [1],
microbiology [2], molecular biology [3] and food science
[4]. As yet, IBD is incompletely understood (or treated)
and the individual patient's response to treatment is vari-
able. Until globally effective treatment is found, there is a
need to decrease the number of relapses of the disease,
lengthen remission and improve quality of life and psy-
chosocial functioning of patients.
The psychology of patients with IBD has been of great
interest to many investigators [5-12]. A number of high
quality studies have shown a link between the patient's
psyche and the course of the disease [5,13,14]. However,
when psychological treatment in the form of psychother-
apy is given most randomized controlled trials in IBD
patients have found it to be ineffective [15-19]. Thus,
some investigators have proposed that treating psycholog-
ical co-morbidities with antidepressants might be of more
utility to control disease activity and lengthen remission,
particularly in Crohn's disease patients [20-23]. This may
be particularly likely because treatment with antidepres-
sants has been found effective in irritable bowel syndrome
(IBS) [24-27], a partly postinfectious disease that com-
monly co-exists with IBD [28,29]. Thus far, a systematic
analysis of available studies assessing the efficacy of anti-
depressant therapy for the control of somatic symptoms
in IBD patients has not been undertaken. Therefore, the
purpose of this study is to examine whether the existing
literature supports a role for antidepressants in managing
inflammatory bowel disease.
Methods
Study selection
Inclusion criteria
All forms of research publications, describing any study
design published between 1990 and 2005, which exam-
ined the use of antidepressants in inflammatory bowel
disease, were included in this review. Participants had to
have a diagnosis of inflammatory bowel disease (either
Crohn's disease or ulcerative colitis or not specified
inflammatory disorder). Studies published before 1990
were not included, as the researchers were mostly inter-
ested in the newest antidepressants, introduced to the
market in the 1990s.
Primary outcome measure
Our primary outcome measure was the efficacy of antide-
pressants in maintaining or inducing remission of inflam-
matory bowel disease. Remission was defined as at least a
4-week period with disease activity at less than 150 points
or a drop in a score of at least 70 points for Crohn's dis-
ease and a score < 2 points or a drop in a score of at least
3 points for ulcerative colitis, measured on the Crohn's
Disease Activity Index and the Simple Clinical Colitis
Activity Index, respectively OR at least a 4-week period
with a complete lack of IBD symptoms [30,31]. Therefore,
the effectiveness of treatment with antidepressants in IBD
patients was defined as the remission of the disease activ-
ity beyond the usual length of remission (different for a
particular patient).
Data source
We electronically searched PubMed, CINAHL, Cochrane
(Cochrane Depression, Anxiety and Neurosis Group and
the Cochrane Inflammatory Bowel Disease and Func-
tional Bowel Disorders group), PsycInfo, and Embase
databases in July 2005 – September 2005 for any studies
published between 1990 and 2005 in which antidepres-
sants were used in inflammatory bowel disease patients.
Follow-up searches were conducted in October and
November 2005 to identify more recently published
papers. We also conducted hand searches of the following
journals:  Gastroenterology,  Current Treatment Options in
Gastroenterology, Psychosomatic Medicine, and General Hos-
pital Psychiatry in September – November 2005.
The search terms used were: Inflammatory Bowel Diseases
OR Inflammatory Bowel Disease OR Colitis, Ulcerative
OR Ulcerative Colitis OR Crohn Disease OR Crohn* Dis-
ease OR Granulomatous Colitis OR Granulomatous
Enteritis OR regional Ileitis OR terminal Ileitis OR Ileocol-
itis OR ibd AND Antidepressive Agents OR antidepress*
OR Thymoanaleptics OR Thymoleptics OR ssri OR mirta-
zapine OR bupropion OR paroxetine OR selective serot-
onin reuptake inhibitor* OR selective norepinephrine
serotonin reuptake inhibitor*. There was no language
restriction. We searched for additional studies in the refer-
ence lists of identified articles. We also searched unpub-
lished theses stored at the University of Adelaide and in
the whole of Australia through the National Library of
Australia. We additionally contacted selected experts (18
South Australian gastroenterologists).
Data extraction
The systematic review identified no randomized control-
led trials, cohort prospective studies nor case-controlled
studies. Nevertheless, we located an open-label study, case
reports, reviews, a guideline, a discussion, and a letter. The
quality of the selected studies was assessed using the
Cochrane Reviewers' Handbook [32]. However, because
all the identified studies were non-randomised we also
used the appendix to this manual prepared by the
Cochrane Non-Randomised Studies Methods Group [33].
The standard components of the quality assessment are:
sample size, allocation concealment, clear description of
treatment, representative source of subjects, use of diag-Clinical Practice and Epidemiology in Mental Health 2006, 2:24 http://www.cpementalhealth.com/content/2/1/24
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nostic criteria or inclusion criteria, outcome measures
described and the use of validated instruments. The
Cochrane Non-Randomised Studies Methods Group has
not specified the components of the quality assessment
for non-randomised trials as yet. We therefore needed to
create our own criteria. As our systematic review identified
mainly case reports, reviews and one open-label study, we
focused in assessing their quality on: length of a treat-
ment, follow-up, clear description of a treatment, descrip-
tion of participants, and the use of validated instruments.
We are aware of the various limitations of these studies.
However, because no other published data exists in this
field it is important to sum up the up-to-date literature as
it may inform and facilitate future randomised trials in
this area.
Data synthesis
As statistical data were accessible only for one study, and
even then were limited, we could not conduct a meta-
analysis.
Results
Description of studies
We identified a total of 106 articles from the electronic
databases, most of which were not directly related to the
entered keywords. Only 12 publications met the inclusion
criteria. During hand searches of journals, and during
searches of reference lists of identified articles and unpub-
lished theses we found no new articles that would match
our inclusion criteria. The contact with selected experts
also failed to identify new papers.
In order of design quality articles that met the inclusion
criteria were: one non-randomised open-label trial, six
case reports, three reviews, one guideline, one discussion
paper, and one letter referring to previous studies. The
total number of IBD patients described was only 20; eight
participants were described in the open-label study and
12 in case reports. Antidepressants described included:
paroxetine, bupropion, amitriptyline, phenelzine and
mirtazapine. Paroxetine was used in three studies in 12
participants. Bupropion was used in two studies in six par-
ticipants, and was recommended for use in IBD patients
in two reviews, one discussion paper and one letter.
Amitriptyline was used in one study in one participant.
Phenelzine was used in one study in one participant. Mir-
tazapine was not recommended in one review (Table 1).
Positive impact of antidepressants on inflammatory bowel 
disease activity
Five research studies indicated a positive impact of the
treatment with antidepressants on the inflammatory
bowel disease activity. Four out of these five studies were
case reports. One study out of the five was an open-label
trial. There were 16 patients treated with antidepressants
in these five studies. All of them benefited from this treat-
ment. Among 16 patients treated with antidepressants,
there were four females, two males, and in 10 the gender
was not specified. Among these patients, seven suffered
from Crohn's disease, one from ulcerative colitis, and 8
from unspecified inflammatory bowel disorder. All
patients were adults. Examined antidepressants were: par-
oxetine (two studies), bupropion (two studies), and
phenelzine (one study).
Two reviews, one discussion paper, and one letter also
endorsed a positive impact of the treatment with antide-
pressants on the inflammatory bowel disease activity,
despite the lack of provision of any new patient data. In all
four of these papers bupropion was recommended for use
in inflammatory bowel disease patients. In one paper,
mirtazapine was not recommended for use in inflamma-
tory bowel disease (See: Discussion for explanation).
Negative impact or no impact of antidepressants on 
inflammatory bowel disease activity
One study, a case report, suggested a potential negative
impact of an antidepressant on inflammatory bowel dis-
ease. Three patients were described, and the antidepres-
sant used was paroxetine. Prior to paroxetine patients had
not been diagnosed with inflammatory bowel disease.
Following treatment with paroxetine for depression,
patients developed chronic diarrhoea and were subse-
quently diagnosed with inflammatory bowel disease,
Crohn's disease in two patients and non-specified inflam-
matory bowel disorder in one patient. There was no con-
trol group in the study however, and the significance of
this observation seems unclear.
Another case report found no impact of antidepressants
on inflammatory bowel disease. One adult, male partici-
pant was described, and the antidepressant used was
transdermal amitriptyline gel. Amitriptyline did not help
the patient with pain nor fully treat the depression, how-
ever, the patient noticed his mood improved.
Quality of studies
We set five quality criteria for analysis: length of treatment
with antidepressant, follow-up, clear description of treat-
ment, description of participants, and validated instru-
ments (See: Table 2).
Five studies met all or four out of five of the quality crite-
ria. One article met three out of five of the quality criteria.
Six publications met only one out of five of the quality cri-
teria. The study by Kast et al. (2001) met all the quality cri-
teria chosen in this systematic review. The next best study
was by Walker et al. (1996). However, the weakness of
this study lay in the fact that the authors did not specify
the IBD type and did not use a disease activity index. TheC
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) Table 1: Features of 12 studies describing the effect of antidepressants on the course of inflammatory bowel disease in order of the quality significance
Study name Design Participants Disease type Method Results
Kast and Altschuler 2001 
(USA)
Case report 2:
Female, 44 y.o., 10 years with CD, CDAI: 202, 
mesalamine 500 mg (2 a day), once a year a 
relapse treated with steroids, depression treated 
with fluoxetine (40 mg) not effectively
Male, 45 y.o., 20 years with CD, CDAI: 275, 
azathioprine (100 mg) and bowel resections, 
fluoxetine for pain not effective.
CD Bupropion 150 mg (3 times daily) for depression 
(a female) and for pain and smoking cessation (a 
male)
Female:19-month remission, bupropion 
dependant, no other medication, CDAI = 0
Male: CDAI = 45, 3–4 diarhoeas daily because of 
ileal-cecal valve, 50 mg azathioprine, still on 
bupropion.
Positive effect of bupropion on IBD activity 
(CD).
Walker et al. 1996 (USA) Non-randomised open 
label study
8, recruited between March and October 1993 in 
tertiary care medical facility in Seattle, English-
speaking, 18 y.o. or older, presented with IBD
Not specified Tools: NIMH Diagnostic Interview Schedule 
(psychiatric interview), GI symptom interview 
and the Briere Child Maltreatment interview 
(history of childhood abuse and neglect), SF-36, 
Tridimensional Personality Questionnaire 
Patients diagnosed with major depression (n = 8) 
have their depression confirmed by the 
Hamilton Depression Inventory (HAM-D) and 
started treatment. Treatment: paroxetine (paxil) 
20 mg, after 1 month two patients had the 
dosage increased to 40 mg. Length: 8 weeks and 
reinterviewed + SF-36 and HAM-D
Decrease in mean HAM-D (pre-treatment 29.0+-
7.8; post-treatment 8.1+-6.1; t = 13.6, df = 7, 
p,0.0001) and significant reduction in functional 
disability on most scales of the SF-36. The SF-36 
measures changes in several domains of patient 
function including physical limitations, 
occupational role, emotional role, social function, 
pain, mental health, vitality, and health perception 
(higher scores associated with increased quality 
of life)
Positive effect of paroxetine on IBD 
activity (not specified).
Scott, Letrent, Hager and 
Burch 1999 (USA)
Case report 1, 42 y.o., black male, depressed with chronic 
abdominal pain, weight loss, insomnia, anhedonia, 
with flare of CD, taking 6-mercaptopurine, 
prednisone and total parenteral nutrition. Treated 
in the past for depression with sertraline 
ineffectively and with amitriptyline successfully.
CD Amitriptyline gel 80 mg/day intramuscularly. 
Improvement in mood but not in pain. Then, 
transdermal gel
Amitriptyline 150 mg applied to the chest at 
bedtime.
Tool: Hamilton Depression Scale
Follow-up 6 weeks. Depression did not respond 
adequately to transdermal amitriptyline, 
however, patient stated that his mood improved. 
Patient's abdominal pain remained unchanged, 
however, did not experience any adverse events 
associated with transdermal medication.
No effect of amitriptyline on IBD activity 
(CD).
Eirund 1998 (Germany) Case report 1, male, 67 y.o., 17 years with UC, 4 relapses per 
year despite the treatment with sulfasalazine
UC Treatment with paroxetine (20 mg) for panic 
disorder
Panic disorder cured. No relapse of UC for 10 
months.
Positive effect of paroxetine on IBD 
activity (UC).
Kast 1998 (USA) Case report 1, female, 33 y.o., 18 years with CD, taking 
azathioprine (75 mg), prednisone (60 mg) and 
acetaminophen (3 tablets daily), 3 bowel 
resections, despite this in relapse
CD Phenelzine treatment for anxiety-prominent 
major depressive episode (15 mg 3 times daily – 
30 mg 3 times daily)
Depression cured. After 7 days of treatment 
bowel movements dropped from 10 to 3–4 per 
day, after the increase to 30 mg 1 bowel 
movement daily, depression responded, no 
cramps. Azathioprine and prednisone tapered off. 
Remission for 2 years until the treatment with 
phenelzine stopped. After 6 weeks since the stop 
relapse.
Positive effect of phenelzine on IBD 
activity (CD).C
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Kane, Altschuler and Kast 
2003 (USA)
Case report 4, (2 women, 2 unspecified) CD Treatment with bupropion
(100 mg daily) for smoking cessation
(2 women) and depression
(2 unspecified)
CDAI<150 within 6 weeks (without a change in 
standard medication for IBD)
Positive effect of bupropion on IBD activity 
(CD).
Torras Bernaldez et al. 
2003 (Spain)
Case report 3 depressed patients, no IBD diagnosed before 
depression
- Treatment with Paroxetine for depression Patients present with chronic diarrhoea, 2 
treated with corticosteroid + 
immunosuppressants, 2 diagnosed with CD, one 
with unspecified bowel disease.
Controversial paroxetine.
Ginsburg et al. 2005 
(USA)
Guideline 0 Not specified NA All antidepressants recommended in 
irritable bowel syndrome recommended in 
IBD.
Kast 2003 (USA) Review NA CD NA Bupropion recommended and mirtazapine 
not recommended.
Kast and Altschuler 2004 
(USA)
Letter NA CD NA Bupropion recommended.
Kast and Altschuler 2005 
(USA)
Review NA CD NA Bupropion recommended.
Kast 2005 Discussion NA CD NA Bupropion recommended.
Legend:
CD – Crohn's disease
CDAI – Crohn's Disease Activity Index
HAM-D – Hamilton Depression Inventory
IBD – inflammatory bowel disease
NIMH – National Institute of Mental Health
SF-36 – Medical Outcome Short Form (36) Health Survey
UC – ulcerative colitis
y.o. – years old
Table 1: Features of 12 studies describing the effect of antidepressants on the course of inflammatory bowel disease in order of the quality significance (Continued)C
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Table 2: Quality assessments in order of the quality significance
Kast et al. 
2001
Walker et 
al. 1996
Scott et al. 
1999
Eirund 1998 Kast 1998 Kane et al. 
2003
Torras et al. 
2003
Ginsburg et 
al. 2005
Kast 2003 Kast et al. 
2004
Kast et al. 
2005
Kast 2005
Length of treatment 2 years 8 weeks 6 weeks 10 months 2 years No data No NA NA NA NA NA
Follow-up Yes, regular 
follow-up for 
2 years
Yes, 2 follow-
up, all 
patients 
completed
Yes, detailed 
every day 
monitoring 
for 6 weeks.
1 follow-up 
after 10 
months
Yes, regular 
follow-up for 
2 years
1 follow-up 
after 6 weeks
Yes NA NA NA NA NA
Clear description of 
treatment
Yes Yes Yes Yes Yes Yes No Yes Yes Yes Yes Yes
Description of 
participants
Yes Yes Yes Yes Yes No No NA NA NA NA NA
Validated 
instruments
Yes Yes, but only 
for 
depression 
and quality of 
life
Yes 
(depression), 
No (CD)
No data No Yes No NA NA NA NA NA
Limitations -D i s e a s e  t y p e  
not specified, 
disease 
activity index 
not used.
Lack of CD 
activity index. 
Focus only on 
depression 
and pain, no 
information 
about 
frequency of 
stools.
No objective 
activity index 
used.
No objective 
activity index 
used.
Lack of 
explanation of 
patients 
characteristic
s, Lack of 
further 
follow-up, no 
length of 
treatment 
provided.
Lack of 
evidence that 
IBD did not 
exist before 
the onset of 
depression, 
no details 
about length 
of treatment, 
no 
description of 
treatment and 
participants, 
no 
information 
about 
instruments.
Guideline 
paper without 
research. IBD 
treated as 
IBS, which 
may not be 
appropriate 
as they are 
different 
conditions.
A review 
study without 
the research. 
Theoretical 
consideration
s only.
A letter 
referring to 
Kane et al. 
2003
A review 
study without 
the research. 
Theoretical 
consideration
s only.
A discussion 
referring to 
Kast et al. 
2001 and 
Kane et al. 
2003
Impact of treatment 
with antidepressants 
on the IBD activity
Positive effect 
of bupropion 
on IBD 
activity (CD).
Positive effect 
of paroxetine 
on IBD 
activity (not 
specified).
No effect of 
amitriptyline 
on IBD 
activity (CD).
Positive effect 
of paroxetine 
on IBD 
activity (UC).
Positive effect 
of phenelzine 
on IBD 
activity (CD).
Positive effect 
of bupropion 
on IBD 
activity (CD).
Controversial 
paroxetine.
All 
antidepressan
ts 
recommende
d in irritable 
bowel 
syndrome 
recommende
d in IBD.
Bupropion 
recommende
d and 
mirtazapine 
not 
recommende
d.
Bupropion 
recommende
d.
Bupropion 
recommende
d.
Bupropion 
recommende
d.
Legend:
CD – Crohn's disease
IBD – inflammatory bowel disease
IBS – irritable bowel syndrome
NA – not applicable
UC – ulcerative colitisClinical Practice and Epidemiology in Mental Health 2006, 2:24 http://www.cpementalhealth.com/content/2/1/24
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study by Scott et al. (1999) also matched the majority of
the quality criteria, however, the researchers did not use a
validated instrument to measure the inflammatory bowel
disease activity, and they focused only on pain and
depression, as their intention was to treat these disorders,
rather than to influence the IBD activity. Eirund et al.'s
(1998) study addressed four out of five quality criteria,
however, these researchers also failed to use an inflamma-
tory bowel disease activity index. The study by Kast (1998)
also met four criteria out of five, but again, the researchers
did not use a validated instrument to measure the inflam-
matory bowel disease activity. Kane et al.'s (2003) study
addressed three out of five criteria. The researchers did not
provide the information about the length of treatment nor
did they describe patients' characteristics and further fol-
low-up. The non-experimental papers [34-38] and the
study by Torras et al. (2003) did not match the quality cri-
teria. Moreover, although their recommendations were of
interest and may help in understanding the problem, they
added no new data.
Discussion
This systematic review is the first structured attempt to
explore the hypothesis that the clinical course of IBD may
be influenced by specifically treating psychological co-
morbidities with antidepressants. Despite widespread
acknowledgement that IBD is not a "6 week illness" [39]
the psychological dimension of the illness has been
largely ignored in standard treatment paradigms. Unfor-
tunately, because of the paucity of published data – both
quantitative and qualitative – this review is unable to pro-
vide a definitive answer on whether IBD can be improved
by antidepressant therapy. However, it has highlighted a
significant "evidence gap" in the literature, supporting our
premise that psychological co-morbidities in patients
with inflammatory bowel disease are often unrecognised
and in general remain under-treated and under-
researched.
While we acknowledge the poor methodological quality
of the collected studies, they do however indicate that
antidepressants appeared not only to help certain individ-
ual patients with IBD cope with their emotional prob-
lems, but also improved their quality of life. The
published observations also hold out the intriguing possi-
bility that antidepressant therapy may have specifically
influenced the course of their inflammatory disease. This
novel therapeutic possibility warrants further considera-
tion.
To date, researchers with an interest in the impact of a
patient's psyche on disease activity in IBD have conducted
little formal research on the use of antidepressants in this
condition, with most published data being uncontrolled
and anecdotal. Only 12 relevant articles were identified,
and five of these did not include new data. However, the
three case reports [20-22], two reviews [35,38], and a dis-
cussion paper [37] did explore the potential for influenc-
ing disease activity in IBD with antidepressants from a
novel perspective. Kast [21] presented a medical history of
a depressed and anxious patient with Crohn's disease who
was treated with phenelzine and subsequently achieved
remission from IBD. In further reports, Kast and Alts-
chuler [22] describe two additional patients who achieved
long-lasting remission of Crohn's disease whilst using
bupropion. These investigators hypothesize that this may
have resulted from decreased tumor necrosis factor-alpha
(TNFα), which is known to play a vital role in Crohn's dis-
ease. Both phenelzine and bupropion increase intracellu-
lar cAMP [40] which, in turn, decreases TNFα. As
phenelzine may cause a hypertensive crisis, bupropion is
suggested to be a safer therapeutic option. Interestingly,
phenelzine and other monoamine oxidase inhibitors
have also been noted to induce remission of rheumatoid
arthritis, a disease in which – as in Crohn's disease – TNFα
has a central role [41]. Kast [35], compared the use of
bupropion and mirtazapine in patients with Crohn's dis-
ease. He speculated that both these antidepressants have
the potential to affect inflammatory responses: bupropion
by lowering TNFα and mirtazapine by increasing its level.
Therefore, according to his hypothesis [35], there are the-
oretical reasons for recommending bupropion and cau-
tioning against mirtazapine when treating depression in
patients with Crohn's disease. Although Kast's explana-
tions appear logical and are supported by other investiga-
tors [20], their practical effectiveness needs to be
experimentally confirmed in appropriate clinical studies.
The largest study in this systematic review, which most
closely matched the standard quality criteria, (See: Data
extraction) was that by Walker, Gelfand et al. (1996).
Whilst comparing IBD patients with and without current
psychological disorders, the investigators noticed that
depressed patients (n = 8) who were given paroxetine in
an open label design showed significant improvement in
relation to functional disability. The researchers had
expected an improvement only in depression, however,
patients' scores on SF-12 also improved in the area of
"physical limitations, occupational role, emotional role,
social function, pain, mental health, vitality, and health
perception, with higher scores associated with increased
quality of life" [23]. Although the importance of this
result seems unquestionable, significant weaknesses of
the study need to be acknowledged. These include the
small sample size, open label design and the fact that the
investigators did not differentiate between patients with
Crohn's disease and ulcerative colitis. However, given the
potential importance of this observation, larger studies
addressing these methodological issues are clearly
needed.Clinical Practice and Epidemiology in Mental Health 2006, 2:24 http://www.cpementalhealth.com/content/2/1/24
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In discussing the possible effects of antidepressant therapy
on IBD as revealed by this systematic review, we acknowl-
edge that all the analysed studies were characterized by
various limitations. Specifically these limitations
included: lack of randomisation or control groups, poten-
tial lack of relevance to ulcerative colitis as most data per-
tain to Crohn's disease, non homogenous participants,
failure to consistently apply standardised instruments,
and lack of routine follow-up tests. Similarly, because of
the uncontrolled nature of the observations, all studies are
open to selection, performance, attrition and detection
bias. Moreover, seven of 12 publications were from the
same group, and four of these were discussions that did
not contain any new data.
The fact that there is little good quality data in this area
does not mean it is unworthy of further study. Our present
state of knowledge regarding the interaction between psy-
chological co-morbidities and IBD resembles that of our
knowledge of the pathogenesis of irritable bowel syn-
drome twenty years ago. At that stage, IBS was thought to
be predominantly a psychological condition, whereas we
now have clear-cut, well accepted evidence of pathological
abnormalities in the gut [42]. Currently IBD is generally
thought to be purely inflammatory, but clinical observa-
tions in individual patients make it hard to dismiss the
potential role of psychological factors [43]. Moreover, it is
well accepted that IBS frequently co-exists in patients with
IBD [28,29] and that both patient groups suffer similar
impairment in physical and psychological domains [28],
making rigid distinctions between psychological versus
inflammatory mechanisms more difficult to uphold. As
antidepressants are widely used in IBS [24-27,44] and
because doctors already empirically treat depression, anx-
iety and pain in IBD using guidelines for IBS [34,43], cre-
ating informed discussion and hopefully prompting
further research in this area is therefore likely to improve
our understanding of IBD and patient care.
Conclusion
Based on our findings, it is not possible to state that anti-
depressants have an impact on the course of inflamma-
tory bowel disease. While they appeared to have a positive
effect in 16 patients in five studies, because studies were
neither randomised nor blinded, it can still be argued that
the outcome may be due to chance. This systematic review
therefore provides insufficient evidence to conclude that
antidepressants are efficacious for the treatment of psy-
chological co-morbidities or somatic complaints, which
do not respond to conventional therapy in IBD patients.
However, the data certainly do not rule out efficacy, and
warrant further properly designed randomised controlled
trials.
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